



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Neuroimaging Correlates of Post-stroke Fatigue

Citation for published version:

Jolly, AA, Zainurin, A, Mead, G & Markus, HS 2023, 'Neuroimaging Correlates of Post-stroke Fatigue: A Systematic Review and Meta-analysis', *International Journal of Stroke*.
<https://doi.org/10.1177/17474930231192214>

Digital Object Identifier (DOI):

[10.1177/17474930231192214](https://doi.org/10.1177/17474930231192214)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

International Journal of Stroke

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



A MEDLINE LISTED, PEER REVIEWED JOURNAL
FOR STROKE PRACTITIONERS AROUND THE WORLD

International Journal of Stroke

OFFICIAL JOURNAL OF THE WORLD STROKE ORGANIZATION

VOLUME 17 • ISSUE 2 • February 2022

ISSN: 1747-4930 • EISSN: 1747-4948



Neuroimaging Correlates of Post-stroke Fatigue: A Systematic Review and Meta-analysis

| | |
|-------------------------------|---|
| Journal: | <i>International Journal of Stroke</i> |
| Manuscript ID | IJS-03-23-10815.R3 |
| Manuscript Type: | Review |
| Date Submitted by the Author: | 04-Jul-2023 |
| Complete List of Authors: | Jolly, Amy A; University of Cambridge, Stroke Research Group, Department of Clinical Neurosciences Zainurin, Adriana; University of Cambridge, Stroke Research Group, Department of Clinical Neurosciences Mead, Gillian; University of Edinburgh, Usher Institute M. rkus, Hugh; University of Cambridge, Stroke Research Group, Department of Clinical Neurosciences |
| Keywords: | Stroke, Fatigue, Post-stroke Fatigue, Neuroimaging, MRI, Systematic Review, Meta-analysis, Neurology |
| | |

SCINCLARONE™
Manuscripts

Neuroimaging Correlates of Post-stroke Fatigue: A Systematic Review and Meta-analysis

Amy A Jolly¹, Adriana Zainurin¹, Gillian Mead², Hugh S Markus¹

1 Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK

2 Usher Institute, The University of Edinburgh, Edinburgh, UK

Keywords: Stroke, Fatigue, MRI, Neuroimaging, Post-stroke fatigue

Word Count: 7,209

Tables and Figures

Table 1. Neuroimaging variable categories and *N* of studies assessing variables.

Table 2. Association of lesion location to PSF categorised by brain region.

Figure 1: PRISMA flow diagram showing study selection process.

Figure 2. Forest plot showing the association between lesion lateralisation (left-sided stroke) and prevalence of PSF.

Corresponding Author: Amy A Jolly, Stroke Research Group, Department of Clinical Neurosciences, University of Cambridge, UK. Email: aj602@medschl.cam.ac.uk

Twitter: @camstroke, @amyajolly

Abstract

Background

Fatigue is a common and disabling symptom following stroke, but its underlying mechanisms are unknown. Associations with a number of imaging features have been proposed.

Aims

We aimed to assess whether neuroimaging parameters could better inform our understanding of possible causes of post-stroke fatigue (PSF) through systematic review and meta-analysis.

Methods

Using a pre-defined protocol registered with PROSPERO (ID: CRD42022303168), we searched EMBASE, MEDLINE, PubMed and PsycInfo for studies assessing PSF and Computerised Tomography (CT)-, Magnetic Resonance (MR)-, Positron Emission Tomography (PET)- imaging or Diffusion Tensor Imaging (DTI). We extracted neuroimaging parameters and narratively analysed study results to assess any association to PSF. Where there were 3+ similar studies, we carried out a meta-analysis using inverse-variance random-effects model to estimate total association of each neuroimaging parameter on PSF. Risk of bias was assessed using the Newcastle and Ottawa Scale.

Results

We identified 46 studies ($N=6,543$); in many studies associations with fatigue were secondary or sub-analyses (28.3%). Imaging parameters were assessed across 8 variables: lesion lateralisation, lesion location, lesion volume, brain atrophy, infarct number, cerebral microbleeds, white matter hyperintensities (WMH) and network measures.

Most variables showed no conclusive evidence for any association with fatigue. Meta-analysis where possible showed no association of the following with PSF; left lesion lateralisation (OR: 0.88, 95% CI [0.64, 1.22], ($p=0.45$)), infratentorial lesion location (OR:

1.83, 95% CI [0.63, 5.32], ($p=0.27$)) and WMH (OR: 1.21, 95% CI [0.84, 1.75], ($p=0.29$)).

Many studies assessed lesion location with mixed findings, only one used voxel-symptom lesion-mapping (VSLM). Some small studies suggested association between altered functional brain networks, namely frontal, fronto-striato-thalamic and sensory processing networks, with PSF.

Conclusion

There was little evidence for association between any neuroimaging parameters and PSF. Future studies should utilise advanced imaging techniques to fully understand the role of lesion location in PSF, whilst the role of altered brain networks in mediating PSF merits further research.

Introduction

Fatigue is a common and often debilitating symptom following both ischaemic and haemorrhagic stroke. It has a major impact on quality of life^{1,2} and has been identified as one of the unmet needs in stroke research.³ Depending on the definition used, estimates of the

prevalence of post-stroke fatigue (PSF) are around 50%.^{4,5} Despite its importance there are no proven treatments for PSF, a fact partly explained by a lack of understanding of its underlying pathophysiology. Potential suggested mechanisms include altered cortical excitability, involvement of specific brain regions, disruption of complex brain networks, and systemic inflammation.⁶

If involvement of specific brain regions or altered brain network activity does play a role, then one might expect neuroimaging to provide important insights into the pathophysiology of PSF. This includes identifying associations with structural anatomical features such as infarct location and size, as well as associations with network integrity and “brain activity”. Most studies describing associations of neuroimaging features with fatigue have been small, and while some have reported associations for example with white matter hyperintensities,⁷ and subcortical infarcts^{7,8} others have not replicated these.^{1,9}

To better understand the relationship between brain structure and function and fatigue, and gain insights into the pathophysiology of PSF, we performed a systematic review of neuroimaging variables and their relationship to PSF.

Methods

In line with PRISMA guidelines¹⁰, the systematic review protocol was pre-registered on PROSPERO (ID: CRD42022303168).¹¹

Searches

We searched four electronic databases using our pre-defined search strategy (available in the Supplement (Appendix 1)) on 20/05/2023. These databases were: EMBASE (from 1974), MEDLINE (from 1946), PubMed (from 1950) and PsycInfo (from 1955). Studies had to

assess fatigue and stroke and neuroimaging to be included in record screening (see search terms, Appendix 1).

Inclusion and Exclusion Criteria

We included randomised controlled trials, observational, cohort, case-control and cross-sectional studies. Only studies in the English language were included.

Studies were included if they assessed stroke patients over 16 years old, with any subtype of stroke (e.g. ischaemic or intracranial haemorrhage), and any duration since stroke. Studies had to include any assessment of fatigue, and at least one of the following imaging modalities: CT-, MR-, PET- imaging or DTI.

Studies were excluded if they assessed patients: under 16, included transient ischaemic attack or subarachnoid haemorrhage or did not assess any of the variables listed above. Grey literature, unpublished literature, abstracts, narrative reviews, and case-reports and series in <5 subjects were excluded.

Data Extraction

Two reviewers (AAJ and AZ) independently screened all titles and abstracts. Any disagreement between reviewers was resolved by discussion between the two reviewers and, if no consensus was obtained, by discussion with a third reviewer (HSM).

Risk of Bias

The Newcastle and Ottawa scale (NOS)¹² was utilised to assess risk of bias. We used the original NOS¹² and the modified NOS for cross-sectional research¹³ (sTable 1). There are no set cut-offs, but higher scores indicate higher quality studies.¹⁴

Data Synthesis

As this was an exploratory review, we planned to look narratively at studies that corrected for confounders and those that did not together. Main findings for each outcome measure were narratively described. Where appropriate, if 3 or more studies were sufficiently similar, in both fatigue measure used and neuroimaging parameter, meta-analysis was performed with R (version 4.2.2) package metafor (v3.8-1),¹⁵ using an inverse-variance random-effects model, to estimate total effect of each neuroimaging measure on PSF. To retain the maximum number of studies in our meta-analyses, we included studies binarizing fatigue using validated cut-offs across multiple measures. We included only raw data or univariate odds ratios in our meta-analyses to ensure consistency in included studies. A p-value of 0.05 was used to determine statistical significance.

Results

Identified studies

Our search strategy identified 5,769 records; 1,858 were duplicates and were removed. Of the remaining 3,911, through title and abstract screening, we identified 46 records that met inclusion criteria. The most common reasons for exclusion were wrong study population ($n=3,026$), not assessing fatigue ($n=2,659$) and case studies ($n=976$). Most excluded studies met multiple exclusion criteria. Searching of reference lists identified a further 32 records, resulting in 78 studies for full-text screen. All full-texts were obtained. Of these, 32 records were excluded (Figure 1). In the case of systematic reviews and meta-analyses, we extracted the studies and included them if they fulfilled inclusion criteria. Based on neuroimaging parameters reported, the remaining 46 studies were divided into 8 subcategories (Table 1). Many studies assessed multiple neuroimaging variables.

The 46 studies comprised a total of 6,543 participants. The most common scale used to assess fatigue was the Fatigue Severity Scale (FSS) ($n=20$ studies), and the second most common the Multidimensional Fatigue Inventory (MFI) ($n=8$). We noted that many studies assessed fatigue as a single construct. Time from stroke to fatigue assessment ranged from the acute stage (<7 days) to 7+ years, the most common timepoint was 3-months post-stroke ($n=18$ studies). Demographics and details of the 46 individual studies are shown in sTable 2.

Associations of PSF with specific neuroimaging variables

Lesion Lateralisation

Twenty-nine studies ($n=3,709$ participants) assessed whether lesion lateralisation was associated with PSF.^{9,16-43} Of these, 24 showed no association, three reported a higher prevalence of PSF with right-sided stroke^{29,34,38} and one showed higher prevalence of PSF in

right-sided stroke at 6-month follow-up but not at baseline.⁴³ One study reported higher rates of general and mental fatigue in those with left-sided lesion lateralisation.⁴²

Sixteen studies had group data or summary data suitable for meta-analysis.^{9,16,17,19,21,24,25,27,28,32,34,37,38,43–45} Two studies had data for both baseline and follow-up,^{9,43} we used only the earliest timepoint to remain consistent with the other studies. One study looked at fatigue across three groups (low, moderate and severe), we collapsed these into two groups: low-moderate (FSS score < 4) vs. severe (FSS score >4), in line with other studies.²⁵ One study had data presented as percentages for two measures, we only included the measure for which percentages could be converted to total sample size.³⁴

On meta-analysis (Figure 2) there was no significant difference between stroke lateralisation and fatigue; OR for left-side lateralisation 0.88 [95% CI 0.64, 1.22] ($p=0.45$). In view of the low-quality score of many studies (sTable 8) we performed a sensitivity analysis excluding lower quality studies, defined as those with a quality score of below half of the maximum score from our meta-analyses (≤ 3 for NOS Cross-sectional and ≤ 4 for NOS Cohort study). Results remained non-significant (OR for left side: 0.86, 95% CI [0.57, 1.29], $p=0.46$).

To assess whether the measure of fatigue used altered results we performed a sensitivity analysis including only a single measure of fatigue ($n=7$ studies^{24,25,28,37,38,43,45}) and the result remained non-significant: OR for left side: 0.67, 95% CI [0.30, 1.47], $p=0.32$.

Lesion Location

Nineteen studies in 3,036 subjects assessed whether there was an association between lesion location and fatigue.^{1,7-9,19,27,29,31,33,38,43,46-53} Lesion locations and study results are summarised in Table 2.

Cortical

Nine studies assessed cortical infarcts, with only one ($n=31$) showing weak association between cortical infarcts and cognitive fatigue.⁸ One study ($n=25$) reported insular lesions to be associated with subjective anergia and tiredness after stroke,⁵² but a more recent study ($n=40$) failed to replicate this finding.³⁸ A further three studies testing overall differences between cortical, subcortical and both cortical and subcortical lesions in PSF found no association.^{7,9,33}

Subcortical

For the purposes of this review we excluded brainstem and cerebellum from the category defined subcortical structures, and rather discussed them in the infratentorial section (see Table 2).

Four studies looked at associations with any subcortical lesions, of which two larger studies ($n=220$ ⁵⁰, $n=109$ ³³) showed no association, while two smaller ones ($n=31$ ⁸, and $n=107$ ⁷) reported an association (Table 2). Of the two positive studies, one reported association between subcortical lesions and higher motor fatigue, higher cognitive fatigue and total fatigue⁸, while the second ($n=107$) reported subcortical infarcts were associated with increased risk of physical PSF at 1-month (OR: 3.15, 95% CI [1.26, 7.86], $p=0.01$) and at 3-months (OR: 2.56, 95% CI [1.07, 6.15], $p=0.04$), and activity-related PSF at 1-month (OR: 2.96, 95% CI [1.17, 7.51], $p=0.02$) and 6-months (OR: 2.71, 95% CI [1.12, 6.58], $p=0.03$).⁷

Four studies assessed basal ganglia lesions.^{1,46,48,49} Three of these studies were conducted by the same research group; we contacted the corresponding author to enquire whether study populations were overlapping but did not receive a reply. Only one out of the three showed an association between acute basal ganglia infarcts and increased PSF risk (OR: 2.08, 95% CI [1.16, 3.75], $p=0.01$), while controlling for sex, depression, instrumental activities of daily living and total number of acute infarcts.⁴⁹

Eight studies assessed thalamic lesions,^{29,43,46–50,53} five studies, four by the same group, showed no association.^{46–50} One study showed thalamus and/or brainstem lesions were associated to PSF²⁹, whilst another found thalamus lesions to be associated with PSF in 230 participants.⁵³ Another study used VSLM to show right thalamus lesions predicted PSF at follow-up ($n=324$) when controlling for age, sex, lesion volume, hypertension, hypercholesterolaemia, BMI, diabetes, smoking, drinking, NIHSS score, stroke classification, depression and Lubben social score (OR: 2.67, 95% CI 1.46– 4.88).⁴³ However, this study showed no significant associations between any lesion location and acute fatigue ($n=361$).⁴³

Only one study ($n=334$) assessed internal capsule lesions and found a higher number of lesions in the fatigued group.⁴⁹ No other subcortical region investigated showed any association with PSF (Table 2).

Infratentorial

Infratentorial lesions were defined as: brainstem, cerebellum, pons, medulla and midbrain (Table 2). Infratentorial lesions were investigated in eight studies. Six ($n=798$) showed no association^{1,27,31,46,48,50}, whilst two found an association with increased PSF risk. One study in 108 participants showed infratentorial infarcts were associated with increased PSF risk at 6-8 weeks post-stroke (OR: 4.69 95% CI 1.03-21.47), on multivariate analyses controlling for age, sex, anxiety, depressive symptoms and disability.⁹ A second study in 107 subjects found an increased risk of global PSF at 3-months (OR: 2.91, 95% CI [1.24, 6.83], $p=0.01$) and at 6-months (OR: 3.19, 95% CI [1.34, 7.58], $p=0.01$) but not at 1-month.⁷

Of seven studies assessing brainstem lesions,^{29,33,38,46,49,50,53} one showed thalamus and/or brainstem lesions predicted general fatigue,²⁹ whilst another ($n=230$) showed brainstem lesions were associated with PSF on univariate analyses, but not when controlling for additional confounders.⁵³ Two studies assessed specific brainstem regions (midbrain, pons, medulla),^{47,50} only one ($n=500$) showed pons infarcts were associated with reduced PSF risk (OR: 0.47, 95% CI [0.26, 0.88], $p=0.02$), after controlling for sex, depression, hyperlipidaemia, Barthel Index score and acute infarcts in the caudate and putamen.⁴⁷ Seven

studies assessed cerebellum lesions,^{33,38,46,47,49,50,53} one study ($n=334$) showed fewer cerebellar infarcts in those with fatigue,⁴⁹ whilst another ($n=230$) showed cerebellar infarcts were associated with PSF at univariate level only.⁵³

Four studies had either infratentorial group data or summary statistics suitable for meta-analysis.^{7,9,27,48} Two studies had data for multiple timepoints; we included only the earliest timepoint for consistency with other studies.⁹ On meta-analysis (sFigure 1) there was no significant association between infratentorial lesions and fatigue; OR: 1.83, 95% CI [0.63, 5.32] ($p=0.27$). Excluding lower quality studies did not alter significance: OR: 1.78, 95% CI [0.54, 5.86], $p=0.34$.

Lesion Volume

Sixteen studies in 2,755 participants tested the association between fatigue and lesion diameter or volume.^{1,7,20,21,31,32,35,43,44,46–51,54} None identified any significant associations (see sTable 4).

Brain Atrophy

Four studies in 540 subjects examined brain atrophy measures in relation to presence and severity of PSF^{1,7,9,39} (sTable 5). All examined associations with global brain volumes, including some subcortical and cortical volumes, and none reported association with PSF. One study ($n=107$) examined specific brain regions and reported no significant associations with PSF.³⁹

Number of Infarcts

Four studies, all from the same author, assessed whether number of acute infarcts were associated with PSF⁴⁶⁻⁴⁹ ($n=1130$) (sTable 6). An initial study showed more acute infarcts in those with PSF,⁴⁹ but three subsequent studies failed to confirm this finding.⁴⁶⁻⁴⁸

Four studies in 922 subjects assessed the relationship between number of old infarcts and presence of PSF (sTable 6). All studies showed no significant relationship.^{1,39,46,47}

Cerebral Microbleeds

Only one study assessed cerebral microbleeds (CMBs) and PSF in 199 subjects.⁴⁸ Deep CMBs (basal ganglia, external capsule, internal capsule and thalamus) were associated with fatigue on univariate analysis ($p=0.038$) and on multivariate analyses in the same population (OR: 2.68, 95% CI: [1.20, 6.00], $p=0.02$) controlling for age, depression, and total number of CMBs.⁴⁸

White Matter Hyperintensities

Seven studies in 1336 subjects assessed the relationship between WMH and PSF^{1,7,9,39,46-48} (sTable 7). All used visual rating scales to assess WMH severity (Fazekas scale in 5, ARWMC scale in 1, and one bespoke grading scale). Six showed no association between WMH severity and PSF.^{1,9,39,46-48} One reported an association with a Fazekas score of 1 and mental fatigue at 3- (OR: 1.54, 95% CI [1.05, 2.21], $p=0.03$) and 6-months (OR: 1.79, 95% CI [1.20, 2.65], $p=0.04$) but not at 1-month.⁷

Three studies had group data or summary statistics available for meta-analysis.^{7,9,47} On meta-analysis (sFigure 2) there was no association between WMH and fatigue; OR: 1.21, 95% CI [0.84, 1.75], ($p=0.29$).

Diffusion tensor imaging (DTI) of white matter ultrastructure

DTI is a sensitive marker of white matter ultrastructural damage in cerebrovascular disease and has been correlated with symptoms such as cognition^{55,56} and apathy⁵⁷ in stroke. At the time of the search strategy, we were unable to find any papers assessing DTI parameters and PSF.

Brain connectivity and network analysis

It has been suggested that cognitive and psychological symptoms arise from damage to anatomically distributed brain networks caused by focal lesions rather than specific lesion locations themselves.⁵⁶ Network disruption is important in mediating the effect of cerebral small vessel disease on both cognition^{55,58} and apathy.⁵⁷ Networks can be assessed structurally using diffusion-weighted imaging and tractography, and functionally using functional MRI (fMRI).

Two studies investigated structural tractography based networks and their relationship to PSF.^{35,44} The first study constructed individual level whole-brain disconnectivity probability maps based on lesion maps from 84 stroke patients, using normative data from healthy controls.³⁵ Non-parametric permutation-based inference was used to conduct voxel-wise analyses on disconnectome maps and estimate regional disconnectivity.³⁵ There was no

association between PSF and any disconnectome measures after accounting for multiple comparisons and controlling for depression.³⁵ A second smaller study used diffusion MRI data from 420 healthy controls to map structural disconnection caused by lesions to the white matter in 12 post-stroke participants.⁴⁴ When all lesions were lateralised to the same hemisphere, voxel-wise correlations showed higher fatigue correlated with greater structural disconnection in an ipsilesional cluster (rostral middle frontal cortex and superior frontal cortex), and a contralesional cluster containing six frontal cortex regions (rostral middle frontal cortex, caudal middle frontal cortex, superior frontal cortex, inferior frontal cortex (pars triangularis and pars opercularis), and caudal anterior cingulate cortex).⁴⁴ When lesions were not lateralised to the same hemisphere no significant associations were observed.⁴⁴

Three studies assessed resting state brain activity markers of PSF using fMRI.^{21,38,44} In 63 stroke subjects, PSF was associated with posterior hypoactivity and prefrontal hyperactivity, as assessed by the amplitude of low-frequency fluctuations (ALFF), which was suggested to reflect dysfunction within large-scale brain systems such as fronto-striatal-thalamic and frontal-occipital networks.²¹ A second study in 16 post-stroke patients reported fractional ALFF was lower in several brain areas in PSF, including the right frontal, right inner orbital frontal, right orbital inferior frontal, right triangular frontal inferior, right anterior and lateral cingulate, and right medial frontal gyri.³⁸ A third small study ($n=12$) used fMRI to show

reduced network functional connectivity in the ipsilesional rostral middle frontal cortex was associated with higher fatigue severity.⁴⁴

Two studies assessed the effect of modafinil on fMRI functional connectivity (FC) in

PSF,^{59,60} using data from the double-blind MIDAS-II trial ($n=36$) which showed modafinil

200mg daily reduced PSF compared to placebo.⁶¹ In a subgroup of 28 who had fMRI,

modafinil treatment was associated with increased resting-state functional connectivity

(rsFC) in the right hippocampus compared to placebo, and lower rsFC in the left

frontoparietal, somatosensory and mesolimbic network.⁵⁹ In a second subgroup study ($n=23$),

FC between the dorsolateral prefrontal cortex and the caudate nucleus was a significant

predictor of reduced PSF after modafinil use.⁶⁰ The authors concluded that fronto-striato-

thalamic FC predicted modafinil response for PSF.⁶⁰

Two studies tested whether disruption of brain asymmetry was associated with PSF.^{45,62} The

first ($n=18$) assessed inter-hemispheric inhibition balance (IIB) using resting state fMRI (rs-

fMRI) and paired-pulse transcranial magnetic stimulation (TMS).⁶² rs-fMRI results showed

that fatigue score was predicted by IIB in the primary motor cortex (M1) but not in the insula,

caudate or thalamus.⁶² Paired-pulse TMS in 41 participants also supported an association

between IIB in the M1 and PSF.⁶² A second study used paired-pulse TMS to show significant

positive correlation between fatigue severity and intracortical facilitation (ICF) asymmetry in a subgroup of participants with fatigue ($n=14$) but no association in the whole cohort ($n=20$).⁴⁵

Risk of Bias Assessment

Using the NOS we identified a moderate level of bias; of a maximum score of 8 or 9 (cross-sectional and cohort studies, respectively) mean(SD) quality score was 4.57(1.14) (sTable 1 for individual study bias estimates).

Discussion

In this systematic review and meta-analysis, carried out using robust methodology according to PRISMA guidelines and including a total of 46 papers ($n=6,543$ subjects), we found no robust relationship between PSF and structural imaging features. Although a minority of papers reported associations these were inconsistent, and most studies reported no association. Considering the totality of the data we found no clear evidence of any association between lesion location or laterality, number of infarcts, WMHs, brain atrophy, or CMBs and PSF. There was sufficient data to perform meta-analysis for lesion lateralisation, WMH and infratentorial lesion location and these were all negative, supporting a lack of any association.

It has been suggested that a number of the cognitive and psychological consequences of stroke may be mediated by damage to distributed brain networks.^{55,56,58} We found limited studies investigating associations between network integrity and PSF. Structural network integrity relies on reconstruction of white matter connections using tractography analysis of DTI. One large study utilising this technique found no association.³⁵ Of note the same technique applied to the same dataset was able to show association between network integrity and post-stroke cognitive impairment, suggesting the technique does have the power to detect associations between symptoms and network dysfunction.⁵⁶ However, a second small study found structural disconnection in several ipsilesional and contralesional frontal brain regions, as well as reduced FC in the ipsilesional rostral middle frontal cortex, associated with PSF.⁴⁴

Functional network measures rely on the BOLD MRI signal, and temporal correlations between activation in different brain regions. In small or moderate sized cohorts these did suggest some potential associations with PSF.^{21,38,44,59,60} It has been hypothesised that fatigue in neurological disorders may relate to alterations in limbic input and motor functions in the basal ganglia, therefore affecting activity in the fronto-striato-thalamic system.⁶³ Consistent with this, one fMRI study identified posterior hypoactivity and prefrontal hyperactivity, which was interpreted to reflect dysfunction within fronto-striatal-thalamic and frontal-

occipital networks.²¹ The MIDAS-II drug trial identified reduced connectivity of the fronto-striatal-thalamus predicted better response to modafinil.⁶⁰ With both structural and functional studies implicating frontal regions,^{21,44,60} future work should further investigate the role of frontal networks in PSF.

Altered perceived effort may also underlie fatigue; it has been suggested that reduced ability to attenuate irrelevant sensory stimuli drives increased perceived effort and causes feelings of fatigue.⁶⁴ One functional network study showed those whose fatigue responded to modafinil treatment had significant decreases in rsFC in somatosensory cortex, inferior parietal lobule and temporal pole.⁵⁹ This may indicate changes within brain areas associated with sensory processing. Specifically, increased activity in these regions at rest, prior to modafinil use and fatigue improvement, could be reflective of overactivity in sensory processing leading to poorer attenuation and, as a result, fatigue. Further, Ondobaka et al. 2022 used rsfMRI to show that IIB in the M1 was associated to, and could predict, fatigue score.⁶² The authors suggest that altered brain asymmetry in the M1 may cause sympathetic central nervous system dominance, leading to higher arousal, poorer sensory attenuation and, thus, fatigue.^{62,65}

Taken together our review suggests anatomical characteristics of the stroke lesion do not relate to PSF. In particular, lesion size and laterality are not important in the pathogenesis of PSF, suggesting clinical care should focus on screening and management of known risk factors, such as inactivity⁶⁶ and mood,⁶⁷ in order to manage PSF.

Whether there is a lack of any relation, or whether the analysis techniques applied have been too simplistic remains uncertain. Taken together, lesion location studies were largely inconclusive with no consistent associations with any particular region; however, one large VSLM study implicated the right thalamus in PSF at 6-months post-stroke but not at baseline.⁴³ Future research should utilise such advanced imaging techniques to further probe the relationship between fatigue and lesion location. It is also possible a more network-based approach is required to identify relationships, and early studies have implicated the frontal,^{38,44} fronto-striato-thalamic^{21,60} and sensory processing networks,^{59,62} but further studies are required to replicate these associations.

It is also possible that perhaps the fatigue measures may have been too simplistic to detect associations between neuroimaging parameters and fatigue. Most studies we identified treated fatigue as a single construct, but this may not be the case. Emerging evidence suggests the cause of PSF to be multidimensional.⁶ Studies have investigated demographic factors, neurological/physical deficits, medical comorbidities, smoking, medications, sleep disturbances, pain, pre-stroke fatigue, depression and anxiety and cognitive impairment as potential risk factors.⁶ It is therefore possible that the same subjective experience of fatigue could result from a number of different mechanisms. The varied response to the modafinil treatment in the MIDAS-II trial further corroborates the heterogenous nature of fatigue.^{59,60} Future research could investigate the inflammation hypothesis: inflammatory response following stroke upregulates pro-inflammatory cytokines causing sickness behaviours, further leading to feelings of fatigue.⁶⁸ Early studies have shown associations between fatigue after stroke and inflammatory markers,^{6,31,68} suggesting a viable avenue for future research.

One limitation of this review is the moderate risk of bias displayed by studies; this is likely to be partially explained by the nature of included studies. Many studies were not designed to specifically investigate fatigue and neuroimaging, rather a number examined these as

secondary or sub-analyses within existing research/research questions (28.3%) (sTable 9), highlighting the infancy of this field and the need for more robust research assessing the pathogenesis of PSF. Some studies included were primary, looking for associations between neuroimaging parameters and fatigue, while in others it was a secondary question. However, sensitivity analysis removing secondary analyses from the meta-analyses did not significantly alter results for either lesion lateralisation or infratentorial location (results not shown). Additional sensitivity analysis excluding these lower quality studies also did not alter the results of the meta-analyses.

The meta-analyses combined studies regardless of fatigue outcome measure used. As noted above, fatigue is a multidimensional construct and different outcome measures may measure different, and perhaps not overlapping, domains.⁶⁶ For the lesion lateralisation meta-analysis there were sufficient studies to perform a sensitivity analysis using only a single measure of fatigue, and this did not alter the results significantly.

Of note, many studies did not control for confounders in the current review; in fact, most carried out only univariate analyses. Some studies did control for key confounders such as

age^{9,21,35, 43, 46,47}, sex^{9,21,43,46,47} and depression^{1, 9,21,29,35,43,46,47}, however, the majority did not.

Age and sex have both been previously associated with fatigue,⁶ whilst depression is a known major confounder in the assessment of fatigue.⁶ It is key that future research should consider and control for these factors, to accurately identify potential correlates of fatigue.

Finally, many studies considered both ischaemic and haemorrhagic stroke, it is important to note that differences in stroke pathophysiology could also mean differing pathomechanisms of fatigue between types of stroke. Future research should aim to assess differences in fatigue across types of stroke.

In conclusion we found little evidence for any association of neuroimaging features with PSF, although for some imaging variables there was limited data available. Several studies implicated altered functional brain networks in PSF, but more work is required to confirm, and fully understand the relevance and clinical implications of such alterations.

References

1. Chen Y-K, Qu J-F, Xiao W-M, et al. Poststroke Fatigue: Risk Factors and its Effect on Functional Status and Health-Related Quality of Life. *Int J Stroke* 2015; 10: 506–512.
2. Naess H, Waje-Andreassen U, Thomassen L, et al. Health-related quality of life among young adults with ischemic stroke on long-term follow-up. *Stroke* 2006; 37: 1232–1236.
3. Rudberg A-S, Berge E, Laska A-C, et al. Stroke survivors' priorities for research related to life after stroke. *Top Stroke Rehabil* 2021; 28: 153–158.
4. Cumming TB, Packer M, Kramer SF, et al. The prevalence of fatigue after stroke: A systematic review and meta-analysis. *Int J Stroke* 2016; 11: 968–977.
5. Chestnut TJ. Fatigue in stroke rehabilitation patients: a pilot study. *Physiother Res Int* 2011; 16: 151–158.
6. Hinkle JL, Becker KJ, Kim JS, et al. Poststroke fatigue: Emerging evidence and approaches to management: A scientific statement for healthcare professionals from the American Heart Association. *Stroke* 2017; 48: e159–e170.
7. Delva M, Delva I. Neuroimaging characteristics and post-stroke fatigue within the first 6 months after ischemic strokes. *Georgian Med News* 2017; 10: 91–95.
8. Hubacher M, Calabrese P, Bassetti C, et al. Assessment of post-stroke fatigue: The fatigue scale for motor and cognitive functions. *Eur Neurol* 2012; 67: 377–384.
9. Snaphaan L, van der Werf S, de Leeuw F-E. Time course and risk factors of post-stroke fatigue: A prospective cohort study. *Eur J Neurol* 2011; 18: 611–617.
10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ* 2021; n71.
11. Jolly AA, Zainurin A, Mead G, et al. Neuroimaging correlates of post-stroke fatigue. *PROSPERO, CRD42022303168*.
12. Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp (n.d., accessed 14 October 2022).
13. Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: A systematic review and meta-analysis. *PLoS One* 2016; 11: e0147601.
14. Harrison JK, Reid J, Quinn TJ, et al. Using quality assessment tools to critically appraise ageing research: a guide for clinicians. *Age Ageing* 2017; 46: 359–365.
15. Viechtbauer W. Conducting meta-analyses in R with the metafor package. *J Stat Softw*; 36. Epub ahead of print 2010. DOI: 10.18637/jss.v036.i03.
16. Lynch J, Mead G, Greig C, et al. Fatigue after stroke: The development and evaluation of a case definition. *J Psychosom Res* 2007; 63: 539–544.
17. Ponchel A, Labreuche J, Bombois S, et al. Influence of medication on fatigue six months after stroke. *Stroke Res Treat* 2016; 1–9.
18. Schepers VP, Visser-Meily AM, Ketelaar M, et al. Poststroke fatigue: course and its relation to personal and stroke-related factors. *Arch Phys Med Rehabil* 2006; 87: 184–8.
19. Appelros P. Prevalence and predictors of pain and fatigue after stroke: a population-based study. *Int J Rehab Res* 2006; 29: 329–333.
20. Chen K, Marsh EB. Chronic post-stroke fatigue: It may no longer be about the stroke itself. *Clin Neurol Neurosurg* 2018; 174: 192–197.
21. Cotter G, Salah Khelif M, Bird L, et al. Post-stroke fatigue is associated with resting state posterior hypoactivity and prefrontal hyperactivity. *Int J Stroke* 2022; 17: 906–913.

22. Duncan F, Lewis SJ, Greig CA, et al. Exploratory longitudinal cohort study of associations of fatigue after stroke. *Stroke* 2015; 46: 1052–1058.
23. Jaracz K, Mielcarek L, Kozubski W. Clinical and psychological correlates of poststroke fatigue. Preliminary results. *Neurol Neurochir Pol* 2007; 41: 36–43.
24. Khan A, Delargy M. Post stroke fatigue; Point prevalence, characterization, associations and radiological correlation in a rehabilitation hospital. *Ir Med J* 2017; 110: 650.
25. Kjeverud A, Østlie K, Schanke A-K, et al. Trajectories of fatigue among stroke patients from the acute phase to 18 months post-injury: A latent class analysis. *PLoS One* 2020; 15: e0231709.
26. Lamb F, Anderson J, Saling M, et al. Predictors of subjective cognitive complaint in post-acute older adult stroke patients. *Arch Phys Med Rehabil* 2013; 94: 1747–1752.
27. Liu X, Kenkare K, Li S, et al. Increased Th17/Treg ratio in poststroke fatigue. *Mediators Inflamm* 2015; 2015: 1–9.
28. Miller KK, Combs SA, Van Puymbroeck M, et al. Fatigue and pain: Relationships with physical performance and patient beliefs after stroke. *Top Stroke Rehabil* 2013; 20: 347–355.
29. Mutai H, Furukawa T, Hourii A, et al. Factors associated with multidimensional aspect of post-stroke fatigue in acute stroke period. *Asian J Psychiatr* 2017; 26: 1–5.
30. Naess H, Nyland HI, Thomassen L, et al. Fatigue at long-term follow-up in young adults with cerebral infarction. *Cerebrovasc Dis* 2005; 20: 245–250.
31. Ormstad H, Aass HCD, Amthor K-F, et al. Serum cytokine and glucose levels as predictors of poststroke fatigue in acute ischemic stroke patients. *J Neurol* 2011; 258: 670–676.
32. Pihlaja R, Uimonen J, Mustanoja S, et al. Post-stroke fatigue is associated with impaired processing speed and memory functions in first-ever stroke patients. *J Psychosom Res* 2014; 77: 380–384.
33. Radman N, Staub F, Aboulafia-Brakha T, et al. Poststroke fatigue following minor infarcts: A prospective study. *Neurology* 2012; 79: 1422–1427.
34. Stein PN, Sliwinski MJ, Gordon WA, et al. Discriminative properties of somatic and nonsomatic symptoms for post stroke depression. *Clin Neuropsychol* 1996; 10: 141–148.
35. Ulrichsen KM, Kolskår KK, Richard G, et al. Structural brain disconnectivity mapping of post-stroke fatigue. *Neuroimage Clin* 2021; 30: 102635.
36. van Eijnsden HM, van de Port IGL, Visser-Meily JMA, et al. Poststroke fatigue: Who is at risk for an increase in fatigue? *Stroke Res Treat* 2012; 2012: 863978.
37. Wang S-S, Wang J-J, Wang P-X, et al. Determinants of fatigue after first-ever ischemic stroke during acute phase. *PLoS One* 2014; 9: e110037.
38. Zhang X, Fang H, Ma D, et al. Risk factors and imaging mechanisms of fatigue after mild ischemic stroke: An exploratory study from a single Chinese center. *Front Neurol* 2021; 12: 649021.
39. Kutlubaev MA, Shenkin SD, Farrall AJ, et al. CT and clinical predictors of fatigue at one month after stroke. *Cerebrovasc Dis Extra* 2013; 3: 26–34.
40. Delva II, Delva MY, Poltorapavlov VA. Clinical factors related to post-stroke fatigue within the first 3 month after acute cerebrovascular events. *Wiad Lek* 2017; 70: 581–585.
41. De Doncker W, Brown KE, Kuppaswamy A. Influence of post-stroke fatigue on reaction times and corticospinal excitability during movement preparation. *Clin Neurophysiol* 2021; 132: 191–199.

42. Tynterova A, Perepelitsa S, Golubev A. Personalized neurophysiological and neuropsychological assessment of patients with left and right hemispheric damage in acute ischemic stroke. *Brain Sci* 2022; 12: 554.
43. Wang J, Gu M, Xiao L, et al. Association of lesion location and fatigue symptoms after ischemic stroke: A VLSM study. *Front Aging Neurosci*; 14. Epub ahead of print 29 June 2022. DOI: 10.3389/fnagi.2022.902604.
44. Schaechter JD, Kim M, Hightower BG, et al. Disruptions in structural and functional connectivity relate to poststroke fatigue. *Brain Connect* 2023; 13: 15–27.
45. Kindred JH, Gregory CM, Kautz SA, et al. Interhemispheric asymmetries in intracortical facilitation correlate with fatigue severity in individuals with poststroke fatigue. *J Clin Neurophysiol*. Epub ahead of print 10 March 2023. DOI: 10.1097/WNP.0000000000000994.
46. Tang WK, Chen YK, Liang HJ, et al. Subcortical white matter infarcts predict 1-year outcome of fatigue in stroke. *BMC Neurol* 2014; 14: 234.
47. Tang WK, Liang HJ, Chen YK, et al. Poststroke fatigue is associated with caudate infarcts. *J Neurol Sci* 2013; 324: 131–135.
48. Tang WK, Liu XX, Chen YK, et al. Cerebral microbleeds and fatigue in stroke. *Eur Neurol* 2014; 71: 213–216.
49. Tang WK, Chen YK, Mok V, et al. Acute basal ganglia infarcts in poststroke fatigue: An MRI study. *J Neurol* 2010; 257: 178–182.
50. Choi-Kwon S, Han SW, Kwon SU, et al. Poststroke fatigue: Characteristics and related factors. *Cerebrovasc Dis* 2005; 19: 84–90.
51. Becker K, Kohen R, Lee R, et al. Poststroke fatigue: Hints to a biological mechanism. *J Stroke Cerebrovasc Dis* 2015; 24: 618–621.
52. Manes F, Paradiso S, Robinson RG. Neuropsychiatric effects of insular stroke. *J Nerv Ment Dis* 1999; 187: 707–712.
53. Zhang H, Liu G, Zhang L, et al. Personalized biomarkers and neuropsychological status can predict post-stroke fatigue. *Brain Sci* 2023; 13: 295.
54. Marsh EB, Lawrence E, Hillis AE, et al. Pre-stroke employment results in better patient-reported outcomes after minor stroke. *Clin Neurol Neurosurg* 2018; 165: 38–42.
55. Lawrence AJ, Zeestraten EA, Benjamin P, et al. Longitudinal decline in structural networks predicts dementia in cerebral small vessel disease. *Neurology* 2018; 90: e1898–e1910.
56. Kolskår KK, Ulrichsen KM, Richard G, et al. Structural disconnectome mapping of cognitive function in poststroke patients. *Brain Behav*; 12. Epub ahead of print 21 August 2022. DOI: 10.1002/brb3.2707.
57. Tay J, Tuladhar AM, Hollocks MJ, et al. Apathy is associated with large-scale white matter network disruption in small vessel disease. *Neurology* 2019; 92: e1157–e1167.
58. Lawrence AJ, Chung AW, Morris RG, et al. Structural network efficiency is associated with cognitive impairment in small-vessel disease. *Neurology* 2014; 83: 304–311.
59. Visser MM, Goodin P, Parsons MW, et al. Modafinil treatment modulates functional connectivity in stroke survivors with severe fatigue. *Sci Rep* 2019; 9: 9660.
60. Visser MM, Maréchal B, Goodin P, et al. Predicting Modafinil-treatment response in poststroke fatigue using brain morphometry and functional connectivity. *Stroke* 2019; 50: 602–609.
61. Bivard A, Lillcrap T, Krishnamurthy V, et al. MIDAS (Modafinil in Debilitating Fatigue After Stroke). *Stroke* 2017; 48: 1293–1298.

62. Ondobaka S, De Doncker W, Ward N, et al. Neural effective connectivity explains subjective fatigue in stroke. *Brain* 2022; 145: 285–294.
63. Chaudhuri A, Behan PO. Fatigue and basal ganglia. *J Neurol Sci* 2000; 179: 34–42.
64. Kuppaswamy A. The fatigue conundrum. *Brain* 2017; 140: 2240–2245.
65. Craig AD (Bud). Forebrain emotional asymmetry: a neuroanatomical basis? *Trends Cogn Sci* 2005; 9: 566–571.
66. Larsson P, Bidonde J, Olsen U, et al. Association of post-stroke fatigue with physical activity and physical fitness: A systematic review and meta-analysis. *Int J Stroke* 2023; 174749302311521.
67. Wu S, Barugh A, Macleod M, et al. Psychological associations of poststroke fatigue: A systematic review and meta-analysis. *Stroke* 2014; 45: 1778–1783.
68. Wen H, Weymann KB, Wood L, et al. Inflammatory signaling in post-stroke fatigue and depression. *Eur Neurol* 2018; 80: 138–148.
69. Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. *BMC Med Res Methodol* 2005; 5: 13.
70. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 10: Analysing data and undertaking meta-analyses. In: Higgins JPT, Thomas J, Chandler J, et al. (eds) *Cochrane Handbook for Systematic Reviews of Interventions version 6.3 (updated February 2022)*. Cochrane, 2022.

Tables and Figures

Table 1. Neuroimaging variable categories and *N* of studies assessing variables

| Neuroimaging category | <i>N</i> of studies | <i>N</i> of participants | References |
|------------------------------|----------------------------|---------------------------------|-----------------------------------|
| Lesion Lateralisation | 29 | 3709 | 9,16–43 |
| Lesion Location | 19 | 3036 | 1,7–9,19,27,29,31,33,38,43,46–53 |
| Lesion Volume | 16 | 2755 | 1,7,20,21,31,32,35,43,44,46–51,54 |
| Brain Atrophy | 4 | 540 | 1,7,9,39 |
| Number of Infarcts | 6 | 1455 | 1,39,46–49 |
| Cerebral Microbleeds | 1 | 199 | 48 |
| WMHs | 7 | 1336 | 1,7,9,39,46–48 |
| Network Measures | 8 | 334 | 21,35,38,44,45,59,60,62 |

Table 2. Association of lesion location to PSF categorised by brain region.

| | Lesion Location | Studies | N | Results |
|-------------|------------------|--|------|---|
| Cortical | Cortical | Nine studies assessed cortical lesions. ^{1,8,33,38,46-50} | 1748 | One showed a small effect size for higher cognitive fatigue. ⁸ |
| | Insula | Two studies assessed insula lesions. ^{38,52} | 65 | Only one showed difference in subjective anergia and underactivity and tiredness ⁵² |
| Subcortical | Subcortical | Four studies assessed subcortical lesions. ^{7,8,33,50} | 467 | One study showed increased risk of physical and activity related PSF with subcortical infarcts. ⁷ Another study showed medium effect size for cognitive and total fatigue and small effect size for motor fatigue. ⁸ |
| | Basal Ganglia | Four studies assessed basal ganglia lesions. ^{1,46,48,49} | 848 | Only one study showed an association for increased risk of PSF with basal ganglia lesions. ⁴⁹ |
| | Thalamus | Eight studies assessed thalamus lesions. ^{29,43,46-50,53} | 2042 | One study showed association between cerebellum, brainstem, and thalamus lesions with PSF at univariate, but not multivariate, level. ⁵³ Another study used VSLM to show right thalamus lesions were associated with fatigue at 6-month follow-up, but not baseline. ⁴³ |
| | Internal Capsule | One study assessed internal capsule lesions. ⁴⁹ | 334 | This study showed a higher number of internal capsule lesions in the fatigued group. ⁴⁹ |
| | Caudate | One study assessed caudate lesions. ⁴⁷ | 500 | This study showed increased risk of PSF associated with caudate lesions. ⁴⁷ |
| | Putamen | One study assessed putamen lesions. ⁴⁷ | 500 | There were a higher number of putamen lesions in the fatigued group, but no association to PSF on multivariate analyses. ⁴⁷ |

| | | | | |
|----------------|----------------------------------|---|------|--|
| | Lacunar Infarcts | One study assessed lacunar infarcts. ¹⁹ | 253 | No association. |
| | Lenticulo-capsular area | One study assessed lenticulo-capsular lesions. ⁵⁰ | 220 | No association. |
| | Globus Pallidus | One study assessed globus pallidus lesions. ⁴⁷ | 500 | No association. |
| | Striatum-thalamus-frontal cortex | One study assessed striatum-thalamus-frontal cortex lesions. ³⁸ | 40 | A trend for higher number of these lesions in the fatigued group was observed. ³⁸ |
| Infratentorial | Infratentorial | Five studies assessed infratentorial lesions. ^{1,7,9,46,48} | 729 | Two found increased risk of PSF associated with infratentorial lesions. ^{7,9} |
| | Infratentorial v Supratentorial | Three studies assessed infratentorial lesions compared to supratentorial lesions. ^{27,31,50} | 284 | No association. |
| | Brainstem | Seven studies assessed brainstem lesions. ^{29,33,38,46,49,50,53} | 1131 | One found fewer brainstem lesions in the fatigued group. ⁴⁹ Another showed thalamus and/or brainstem lesions were associated with increased PSF risk. ²⁹ A third showed association between cerebellum, brainstem, and thalamus lesions with PSF at univariate, but not multivariate, level. ⁵³ |
| | Cerebellum | Seven studies assessed cerebellum lesions. ^{33,38,46,47,49,50,53} | 1530 | One found fewer cerebellum lesions in the fatigued group. ⁴⁹ Another showed association between cerebellum, brainstem, and thalamus lesions with PSF at univariate, but not multivariate, level. ⁵³ |
| | Pons | Two studies assessed pons lesions. ^{47,50} | 720 | Only showed reduced risk of PSF associated with pons lesions ⁴⁷ |
| | Medulla | Two studies assessed medulla lesions. ^{47,50} | 720 | No association. |
| | Midbrain | Two studies assessed midbrain lesions. ^{47,50} | 720 | No association. |

| | | | | |
|--------------------------|--------------------------|---|-----|-----------------|
| Cortical and Subcortical | Cortical and Subcortical | Two studies compared having both cortical and subcortical lesions. ^{8,9} | 139 | No association. |
| | Cortical-Subcortical | Two studies assessed cortical-subcortical lesions. ^{7,33} | 216 | No association. |
| Other | Infarct location | One study assessed infarct location. ⁵¹ | 39 | No association. |

Note. n=3036. Full study details and results available in sTable 3.

Peer Review Version



Figure 1. PRISMA flow diagram¹⁰ showing the selection process

Figure 2. Forest plot showing the association between lesion lateralisation (left-sided stroke) and prevalence of PSF.



Note. Liu et al. 2015²⁷ and Kjeverud et al. 2020²⁵ compare low-moderate vs. severe fatigue. For Pihlaja et al. 2014³², Snaphaan et al. 2011⁹ and Stein et al. 1996³⁴ group data calculated using percentages

Peer Review Version

Sources of Funding

A.A. Jolly's studentship is supported by the Stroke Association R4VaD grant (RRZA/199);

A. Zainurin is supported by the Tun Taib Foundation Scholarship; G. Mead and H.S. Markus

report no relevant funding. This research was supported by the NIHR Cambridge Biomedical

Research Centre (NIHR203312). The views expressed are those of the author and not

necessarily those of the NIHR or the Department of Health and Social Care

Disclosures

AAJ, AZ and HSM report no relevant disclosures. GM receives royalties from Later Life

Training and Elsevier and Consultancy fees from Imperative Care.

Supplemental Material

Appendix 1

sFigures 1-2

sTables 1-9